GLP-1 drugs were also associated with a slight increase in risk for kidney cancer. The increase was not statistically ...

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

According to a report by the Financial Times, Morgan & Morgan, a law firm, revealed it had filed a case on behalf of a ...

US President Donald Trump has backed down from setting high tariffs on pharmaceuticals and semiconductors imported from the ...

TORONTO, Aug. 22, 2025 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with ...

Pedersen and Maggie Fick COPENHAGEN (Reuters) -As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the ...

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Ascendis Pharma's TransCon platform shows promise, but challenges with rollout, competition, and execution risks lead to a ...

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a ...